N-(4-methoxymethyl-benzyl)-acetamide | 861798-21-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-methoxymethyl-benzyl)-acetamide
• 英文别名: Acetyl-(4-methoxymethyl-benzylamin)；N-(4-Methoxymethyl-benzyl)-acetamid；N-[[4-(methoxymethyl)phenyl]methyl]acetamide
• CAS: 861798-21-2
• 化学式: C₁₁H₁₅NO₂
• mdl: MFCD24390596
• 分子量: 193.246
• InChiKey: BBXGRIMNQXJNQJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(4-methoxymethyl-benzyl)-acetamide 在 盐酸 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 生成 1-(4-(Methoxymethyl)phenyl)-N-methylmethanamine
  参考文献：
  名称：

  Chemical ionization mass spectrometry of bifunctional compounds. The behaviour of bifunctional compounds on protonation

  摘要：

  AbstractPositive‐ion chemical ionization mass spectra were measured for simple bifunctional aromatic compounds of the type p‐XCH2C6H4CH2Y, where X = NH2, NH(CH3) and N(CH3)2 and Y = OH and OCH3. For each compound, essentially only three peaks of ions, [MH]+, [ MH ‐ XH] + and [MH ‐ YH] +, appeared. The B/E con stant linked‐scan spectra showed that the stable non‐decomposing [MH]+ had the proton only on the nitrogen‐containing functional group. From these data, the relative amounts of total protonation, the ratio of N‐and O‐protonation and the fraction of fragmenting [MH]+ can be calculated. The ease of protonation (protonation susceptibility) and the reactivity (fragmentation capability) of the respective functional groups are discussed.

  DOI：

  10.1002/oms.1210251205
• 作为产物：
  描述：

  4-(羟甲基)苯甲腈 在 sodium hydride 、 溶剂黄146 、 diborane(6) 作用下， 以 四氢呋喃 为溶剂， 生成 N-(4-methoxymethyl-benzyl)-acetamide
  参考文献：
  名称：

  Chemical ionization mass spectrometry of bifunctional compounds. The behaviour of bifunctional compounds on protonation

  摘要：

  AbstractPositive‐ion chemical ionization mass spectra were measured for simple bifunctional aromatic compounds of the type p‐XCH2C6H4CH2Y, where X = NH2, NH(CH3) and N(CH3)2 and Y = OH and OCH3. For each compound, essentially only three peaks of ions, [MH]+, [ MH ‐ XH] + and [MH ‐ YH] +, appeared. The B/E con stant linked‐scan spectra showed that the stable non‐decomposing [MH]+ had the proton only on the nitrogen‐containing functional group. From these data, the relative amounts of total protonation, the ratio of N‐and O‐protonation and the fraction of fragmenting [MH]+ can be calculated. The ease of protonation (protonation susceptibility) and the reactivity (fragmentation capability) of the respective functional groups are discussed.

  DOI：

  10.1002/oms.1210251205

文献信息

• [EN] SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1<br/>[FR] PYRIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE DNMT1
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017216726A1

  公开（公告）日：2017-12-21

  The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及取代吡啶衍生物。具体而言，该发明涉及符合以下式（Iar）的化合物：（Iar）其中Yar、X1ar、X2ar、R1ar、R2ar、R3ar、R4ar和R5ar如本文所定义；或其药学上可接受的盐或前药。该发明的化合物是DNMT1的选择性抑制剂，可用于治疗癌症、癌前综合征、β血红蛋白病、镰状细胞病、镰状细胞贫血、β地中海贫血以及与DNMT1抑制相关的疾病。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制DNMT1活性和治疗相关疾病的方法。
• [EN] SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1<br/>[FR] PYRIDINES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE DNMT1
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017216727A1

  公开（公告）日：2017-12-21

  The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.